{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T01:12:50Z","timestamp":1781313170394,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Medical Award Foundation","award":["YXJL-2020-0785-0655"],"award-info":[{"award-number":["YXJL-2020-0785-0655"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-99889-7","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T06:05:05Z","timestamp":1747807505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world comparison of neoadjuvant chemoimmunotherapy and chemotherapy in muscle-invasive bladder cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Xinjia","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"99889_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41585-022-00591-4","volume":"19","author":"D Theodorescu","year":"2022","unstructured":"Theodorescu, D., Li, Z. & Li, X. Sex differences in bladder cancer: emerging data and call to action. Nat. Rev. Urol. 19, 447\u2013449. https:\/\/doi.org\/10.1038\/s41585-022-00591-4 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"99889_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han, B. et al. Cancer incidence and mortality in China, 2022. J. Natl. Cancer Cent. 4, 47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006 (2024).","journal-title":"J. Natl. Cancer Cent."},{"key":"99889_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes, J. et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur. Urol. 85, 17\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.016 (2024).","journal-title":"Eur. Urol."},{"key":"99889_CR4","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/jco.2010.32.3139","volume":"29","author":"G Griffiths","year":"2011","unstructured":"Griffiths, G., Hall, R., Sylvester, R., Raghavan, D. & Parmar, M. K. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 29, 2171\u20132177. https:\/\/doi.org\/10.1200\/jco.2010.32.3139 (2011).","journal-title":"J. Clin. Oncol."},{"key":"99889_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/ju.0000000000002189","volume":"207","author":"HD Patel","year":"2022","unstructured":"Patel, H. D. et al. Four versus 3 cycles of neoadjuvant chemotherapy for Muscle-Invasive bladder cancer: implications for pathological response and survival. J. Urol. 207, 77\u201385. https:\/\/doi.org\/10.1097\/ju.0000000000002189 (2022).","journal-title":"J. Urol."},{"key":"99889_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/cncr.25429","volume":"117","author":"GV Raj","year":"2011","unstructured":"Raj, G. V. et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 117, 276\u2013282. https:\/\/doi.org\/10.1002\/cncr.25429 (2011).","journal-title":"Cancer"},{"key":"99889_CR7","doi-asserted-by":"publisher","unstructured":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. European urology. 48, 202\u2013205; discussion 205\u2013206, (2005). https:\/\/doi.org\/10.1016\/j.eururo.2005.04.006","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"99889_CR8","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.euo.2018.09.004","volume":"2","author":"L Boeri","year":"2019","unstructured":"Boeri, L. et al. Delaying radical cystectomy after neoadjuvant chemotherapy for Muscle-invasive bladder Cancer is associated with adverse survival outcomes. Eur. Urol. Oncol. 2, 390\u2013396. https:\/\/doi.org\/10.1016\/j.euo.2018.09.004 (2019).","journal-title":"Eur. Urol. Oncol."},{"key":"99889_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","volume":"34","author":"AV Balar","year":"2023","unstructured":"Balar, A. V. et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Annals Oncology: Official J. Eur. Soc. Med. Oncol. 34, 289\u2013299. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.012 (2023).","journal-title":"Annals Oncology: Official J. Eur. Soc. Med. Oncol."},{"key":"99889_CR10","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant Atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706\u20131714. https:\/\/doi.org\/10.1038\/s41591-019-0628-7 (2019).","journal-title":"Nat. Med."},{"key":"99889_CR11","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/jco.21.01003","volume":"39","author":"TL Rose","year":"2021","unstructured":"Rose, T. L. et al. Phase II study of gemcitabine and Split-Dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with Muscle-Invasive bladder Cancer. J. Clin. Oncol. 39, 3140\u20133148. https:\/\/doi.org\/10.1200\/jco.21.01003 (2021).","journal-title":"J. Clin. Oncol."},{"key":"99889_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00822-0","author":"K Li","year":"2024","unstructured":"Li, K. et al. Neoadjuvant gemcitabine-cisplatin plus Tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial. Nat. cancer. https:\/\/doi.org\/10.1038\/s43018-024-00822-0 (2024).","journal-title":"Nat. cancer"},{"key":"99889_CR13","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1200\/jco.23.00363","volume":"41","author":"R Cathomas","year":"2023","unstructured":"Cathomas, R. et al. Perioperative chemoimmunotherapy with durvalumab for Muscle-Invasive urothelial carcinoma: primary analysis of the Single-Arm phase II trial SAKK 06\/17. J. Clin. Oncol. 41, 5131\u20135139. https:\/\/doi.org\/10.1200\/jco.23.00363 (2023).","journal-title":"J. Clin. Oncol."},{"key":"99889_CR14","unstructured":"Brierley, J. D. & Wittekind, G. M. C. TNM classification of malignant tumors. UICC International Union Against Cancer. 8th edn. Available online: https:\/\/www.uicc.org\/what-we-do\/sharing-knowledge\/tnm\/publications-and-resources (accessed on."},{"key":"99889_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M. & Reuter, V. E. The 2016 WHO classification of tumours of the urinary system and male genital Organs-Part B: prostate and bladder tumours. Eur. Urol. 70, 106\u2013119. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.028 (2016).","journal-title":"Eur. Urol."},{"key":"99889_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel, V. G., Oh, W. K. & Galsky, M. D. Treatment of muscle-invasive and advanced bladder cancer in 2020. Cancer J. Clin. 70, 404\u2013423. https:\/\/doi.org\/10.3322\/caac.21631 (2020).","journal-title":"Cancer J. Clin."},{"key":"99889_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t, L. et al. Bladder cancer. Nat. Reviews Disease Primers. 9, 58. https:\/\/doi.org\/10.1038\/s41572-023-00468-9 (2023).","journal-title":"Nat. Reviews Disease Primers"},{"key":"99889_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/s1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma, P. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 18, 312\u2013322. https:\/\/doi.org\/10.1016\/s1470-2045(17)30065-7 (2017).","journal-title":"Lancet Oncol."},{"key":"99889_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s1470-2045(17)30900-2","volume":"19","author":"MR Patel","year":"2018","unstructured":"Patel, M. R. et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 19, 51\u201364. https:\/\/doi.org\/10.1016\/s1470-2045(17)30900-2 (2018).","journal-title":"Lancet Oncol."},{"key":"99889_CR20","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt, J. et al. Pembrolizumab as Second-Line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683 (2017).","journal-title":"N. Engl. J. Med."},{"key":"99889_CR21","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/s1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar, A. V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483\u20131492. https:\/\/doi.org\/10.1016\/s1470-2045(17)30616-2 (2017).","journal-title":"Lancet Oncol."},{"key":"99889_CR22","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/bju.15434","volume":"128","author":"P Ravi","year":"2021","unstructured":"Ravi, P. et al. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU Int. 128, 607\u2013614. https:\/\/doi.org\/10.1111\/bju.15434 (2021).","journal-title":"BJU Int."},{"key":"99889_CR23","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/jco.21.01485","volume":"40","author":"SA Funt","year":"2022","unstructured":"Funt, S. A. et al. Neoadjuvant Atezolizumab with gemcitabine and cisplatin in patients with Muscle-Invasive bladder cancer: A multicenter, Single-Arm, phase II trial. J. Clin. Oncol. 40, 1312\u20131322. https:\/\/doi.org\/10.1200\/jco.21.01485 (2022).","journal-title":"J. Clin. Oncol."},{"key":"99889_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nature11986","volume":"496","author":"GM Tannahill","year":"2013","unstructured":"Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1\u03b2 through HIF-1\u03b1. Nature 496, 238\u2013242. https:\/\/doi.org\/10.1038\/nature11986 (2013).","journal-title":"Nature"},{"key":"99889_CR25","doi-asserted-by":"publisher","unstructured":"Nagy, M. Z. et al. Effector T cells under hypoxia have an altered transcriptome similar to tumor-stressed T cells found in non-responsive melanoma patients. J. Immunother. Cancer. 13 https:\/\/doi.org\/10.1136\/jitc-2024-010153 (2025).","DOI":"10.1136\/jitc-2024-010153"},{"key":"99889_CR26","doi-asserted-by":"publisher","first-page":"1549276","DOI":"10.3389\/fimmu.2025.1549276","volume":"16","author":"S Shi","year":"2025","unstructured":"Shi, S., Ou, X., Liu, C., Wen, H. & Ke, J. Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment. Front. Immunol. 16, 1549276. https:\/\/doi.org\/10.3389\/fimmu.2025.1549276 (2025).","journal-title":"Front. Immunol."},{"key":"99889_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen, Z., Han, F., Du, Y., Shi, H. & Zhou, W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal. Transduct. Target. Therapy. 8, 70. https:\/\/doi.org\/10.1038\/s41392-023-01332-8 (2023).","journal-title":"Signal. Transduct. Target. Therapy"},{"key":"99889_CR28","doi-asserted-by":"publisher","unstructured":"Xie, Y. et al. Inflammation in cancer: therapeutic opportunities from new insights. Mol. Cancer. 24 https:\/\/doi.org\/10.1186\/s12943-025-02243-8 (2025).","DOI":"10.1186\/s12943-025-02243-8"},{"key":"99889_CR29","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859\u2013866. https:\/\/doi.org\/10.1056\/NEJMoa022148 (2003).","journal-title":"N. Engl. J. Med."},{"key":"99889_CR30","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1002\/cncr.32169","volume":"125","author":"A Martini","year":"2019","unstructured":"Martini, A. et al. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. Cancer 125, 3155\u20133163. https:\/\/doi.org\/10.1002\/cncr.32169 (2019).","journal-title":"Cancer"},{"key":"99889_CR31","doi-asserted-by":"publisher","first-page":"viii726","DOI":"10.1093\/annonc\/mdy424.039","volume":"29","author":"CJ Hoimes","year":"2018","unstructured":"Hoimes, C. J. et al. A phase Ib\/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC). Ann. Oncol. 29, viii726. https:\/\/doi.org\/10.1093\/annonc\/mdy424.039 (2018).","journal-title":"Ann. Oncol."},{"key":"99889_CR32","doi-asserted-by":"publisher","unstructured":"Yu, L. et al. Bidirectional interaction between Cancer cells and platelets provides potential strategies for Cancer therapies. Front. Oncol. 11 https:\/\/doi.org\/10.3389\/fonc.2021.764119 (2021).","DOI":"10.3389\/fonc.2021.764119"},{"key":"99889_CR33","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1159\/000343278","volume":"89","author":"C Can","year":"2012","unstructured":"Can, C. et al. Pretreatment parameters obtained from peripheral blood sample predicts invasiveness of bladder carcinoma. Urol. Int. 89, 468\u2013472. https:\/\/doi.org\/10.1159\/000343278 (2012).","journal-title":"Urol. Int."},{"key":"99889_CR34","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1002\/cam4.1686","volume":"7","author":"Y Miyama","year":"2018","unstructured":"Miyama, Y. et al. The prognostic value of PD-L1 expression in upper tract urothelial carcinoma varies according to platelet count. Cancer Med. 7, 4330\u20134338. https:\/\/doi.org\/10.1002\/cam4.1686 (2018).","journal-title":"Cancer Med."},{"key":"99889_CR35","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-018-0205-5","volume":"24","author":"L Zhao","year":"2018","unstructured":"Zhao, L. et al. Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells. Nat. Med. 24, 1536\u20131544. https:\/\/doi.org\/10.1038\/s41591-018-0205-5 (2018).","journal-title":"Nat. Med."},{"key":"99889_CR36","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1200\/jco.2009.25.4599","volume":"28","author":"J Bellmunt","year":"2010","unstructured":"Bellmunt, J. et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J. Clin. Oncol. 28, 1850\u20131855. https:\/\/doi.org\/10.1200\/jco.2009.25.4599 (2010).","journal-title":"J. Clin. Oncol."},{"key":"99889_CR37","doi-asserted-by":"publisher","first-page":"175883592097004","DOI":"10.1177\/1758835920970049","volume":"12","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Therapeutic Adv. Med. Oncol. 12, 1758835920970049. https:\/\/doi.org\/10.1177\/1758835920970049 (2020).","journal-title":"Therapeutic Adv. Med. Oncol."},{"key":"99889_CR38","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1159\/000489152","volume":"46","author":"S Wu","year":"2018","unstructured":"Wu, S. et al. Pretreatment Neutrophil-Lymphocyte ratio as a predictor in bladder Cancer and metastatic or unresectable urothelial carcinoma patients: a pooled analysis of comparative studies. Cell. Physiol. Biochemistry: Int. J. Experimental Cell. Physiol. Biochem. Pharmacol. 46, 1352\u20131364. https:\/\/doi.org\/10.1159\/000489152 (2018).","journal-title":"Cell. Physiol. Biochemistry: Int. J. Experimental Cell. Physiol. Biochem. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99889-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99889-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99889-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T06:05:10Z","timestamp":1747807510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99889-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["99889"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-99889-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the ethics committee of the Peking University First Hospital (Number: 2020\u2013303) and conducted in accordance with the guidelines of the ethics committee and the 1964 Declaration of Helsinki and its later amendments. Due to the retrospective nature of the study, Peking University First Hospital ethics committee waived the need of obtaining informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"17588"}}